wild casino $300 Palvella Therapeutics to debut on Nasdaq under the ticker symbol "PVLA" as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases Strong balance sheet with approximately $80.0 million of cash and cash equivalents, including proceeds from a PIPE financing co-led by BVF Partners, L.P. and Frazier Life Sciences Cash expected to fund operations into the second half of 2027, including through Phase 3 SELVA clinical trial of QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) and Phase 2 clinical trial in cutaneous venous malformations (cutaneous VMs) Microcystic LMs is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. QTORINTM rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous VMs WAYNE, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol "PVLA". Palvella will continue to be led by Wes Kaupinen, its Founder and Chief Executive Officer, and other members of the Palvella management team. The transaction was approved by Pieris stockholders at a special meeting held on December 11, 2024, and the transaction had been previously approved by Palvella stockholders. "With strong support from leading healthcare-dedicated investors, Palvella is well positioned to enter the public markets and pursue our vision of becoming the leading rare disease company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases," said Mr. Kaupinen. "This transaction will enable us to accelerate late-stage development of QTORINTM rapamycin, our lead product candidate, for microcystic LMs and cutaneous VMs while also further advancing additional novel product candidates from our QTORINTM platform." Concurrent with the merger, Palvella completed a previously announced oversubscribed $78.9 million private placement co-led by BVF Partners, L.P., an existing investor, and Frazier Life Sciences, a new investor, and with participation from a syndicate of leading healthcare-dedicated investors. Additional new investors include Blue Owl Healthcare Opportunities, Nantahala Capital, DAFNA Capital Management, ADAR1 Capital Management, and a healthcare dedicated fund. Existing investors Samsara BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an AscellaHealth partner company), BioAdvance, and Gore Range Capital also participated in the financing. Palvella's cash and cash equivalents of approximately $80.0 million is expected to fund operations into the second half of 2027, including through results from the SELVA Phase 3 clinical trial of QTORINTM rapamycin for the treatment of microcystic LMs and Phase 2 clinical trial of QTORINTM rapamycin in cutaneous VMs. Palvella's research team developed QTORINTM, a patented and versatile platform designed to generate novel topical therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of serious, rare genetic skin diseases. Well-accepted mechanisms of action of rapamycin and other therapeutic agents represent potential therapies for rare genetic skin diseases. However, the adverse event profile of those agents through systemic exposure poses significant barriers to patient adoption. Palvella's QTORINTM product candidates are designed for targeted, localized delivery of therapeutic agents to pathogenic tissue of interest while minimizing systemic absorption and thereby reducing the risk of unwanted adverse events associated with systemic therapy. Palvella's lead product candidate QTORINTM rapamycin is a novel, patented 3.9% rapamycin anhydrous gel currently under development for the treatment of microcystic LMs, cutaneous VMs, and other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. QTORINTM rapamycin has received FDA Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for microcystic LMs and is the recent recipient of up to a $2.6 million FDA Orphan Products Grant. QTORINTM rapamycin has also received Fast Track Designation for venous malformations. QTORINTM rapamycin is protected by issued composition patents covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S., Japan, Australia, China and Israel and pending patent applications broadly covering anhydrous gel formulations of rapamycin, as well as methods of use, in the U.S. and other countries. In the third quarter of 2024, Palvella initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORINTM rapamycin administered once daily for the treatment of microcystic LMs. The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment (mLM-IGA) at week 24. The Phase 3 study is enrolling approximately 40 subjects, age six or older, at leading vascular anomaly centers across the U.S. Transaction Details Based on the final exchange ratio of approximately 0.30946 shares of Pieris common stock for each share of Palvella common stock, at the closing of the merger, there are approximately 13.95 million shares of the combined company's common stock outstanding on a diluted basis, with prior Pieris stockholders owning approximately 11% on a diluted basis and prior Palvella stockholders (including investors in the private placement) holding approximately 89% of the combined company's outstanding common stock on a diluted basis. In connection with the closing of the merger, Pieris issued a non-transferable contingent value right (CVR) to Pieris shareholders of record immediately prior to the closing, which does not include the former holders of shares of Palvella or the private financing investors. Holders of the CVR will be entitled to receive payments from proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to other potential licensing agreements involving certain of Pieris' legacy assets, as well as certain potential payments related to historical research and development tax credits, which may or may not be realized. TD Cowen served as lead placement agent and Cantor served as a placement agent for Palvella's concurrent financing. Troutman Pepper Hamilton Sanders LLP served as legal counsel to Palvella. Cooley LLP served as legal counsel to the placement agents. Stifel served as the exclusive financial advisor to Pieris and Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. served as legal counsel to Pieris. About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mTOR pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs are persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States. About Palvella Therapeutics Founded and led by rare drug disease drug development veterans, Palvella Therapeutics PVLA is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORINTM platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORINTM 3.9% rapamycin anhydrous gel (QTORINTM rapamycin), is currently in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow the Company on LinkedIn. QTORINTM rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella and Pieris, as well as assumptions made by, and information currently available to, management of Palvella and Pieris. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, the sufficiency of the combined company's capital resources; the combined company's cash runway; the expected timing of the closing of the proposed transactions; statements regarding the potential of, and expectations regarding, Palvella's programs, including QTORINTM rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity; the expected timing of initiating, as well as the design of Palvella's Phase 2 clinical trial of QTORINTM rapamycin in cutaneous venous malformations. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the limited operating history of each company; the significant net losses incurred since inception; the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella's product candidates, including QTORINTM rapamycin; the outcome of early clinical trials for Palvella's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella's limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella's current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of the global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella and Pieris to protect their respective intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Pieris' most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, as well as the registration statement on Form S-4 filed with the SEC by Pieris in connection with the merger. Palvella and Pieris can give no assurance that the conditions to the proposed transactions will be satisfied. Except as required by applicable law, Palvella and Pieris undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Palvella Therapeutics Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics wes.kaupinen@palvellatx.com Media Stephanie Jacobson Managing Director, Argot Partners palvella@argotpartners.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Two men have been arrested in connection with a £20k robbery. The two suspects threatened staff at the Vodafone store in Marlborough High Street around 4pm yesterday (Saturday), before leaving with approximately £20,000 worth of stock. They were arrested on suspicion of robbery following a brief pursuit on the A338 near Hungerford and are currently in police custody. The driver was further arrested on suspicion of dangerous driving. Wiltshire Police is appealing for anyone who witnessed the incident or with dashcam or CCTV footage to contact them on 101, quoting log 181 and the date of the incident. Alternatively, leave information anonymously by calling Crimestoppers on 0800 555111.Michelle Keegan & Mark Wright took secret pregnancy picture WEEKS ago & hid her baby bump before big revealSAN DIEGO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired The Toronto-Dominion Bank (NYSE: TD) securities between February 29, 2024 and October 9, 2024. TD is an international bank, operating through four segments: Canadian Personal and Commercial Banking, U.S. Retail, Wealth Management and Insurance, and Wholesale Banking. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that The Toronto-Dominion Bank (TD) Misled Investors Regarding Compliance with its Anti-Money Laundering Program According to the complaint, defendants failed to disclose the issues surrounding TD's anti-money laundering ("AML") program employed to comply with the U.S. Bank Secrecy Act ("BSA"), the ability for defendants to "fix" those issues, and the punitive and remedial compliance measures likely to be imposed upon TD through the resolution of these investigation. Specifically, defendants concealed or otherwise minimized the significance of the failures of the Company’s AML program and made no indication that the imposition of an asset cap or other punitive or compliance measures would be imposed that would undermine TD’s continued growth for the foreseeable future. On October 10, 2024, TD unveiled the resolutions reached from a previously disclosed investigations related to its Bank Secrecy Act and Anti-Money Laundering compliance programs, which included, in addition to the punitive payment of $3.09 billion, both an asset cap, preventing TD’s U.S. subsidiaries from exceeding a collective $434 billion, a reflection of the Company’s assets as of September 30, 2024, and further subjects TD to more stringent approval processes for its product, service, and market rollouts. Further, the Department of Justice, in their own corresponding release, highlighted the significance of TD’s failures as “the largest bank in U.S. history to plead guilty to Bank Secrecy Act program failures, and the first US bank in history to plead guilty to conspiracy to commit money laundering.” On this news, the price of TD’s common stock fell from a closing market price of $63.51 per share on October 9, 2024, to $59.44 per share on October 10, 2024, and further to $57.01 on October 11, 2024, a decline of more than 10% in the span of just two days. What Now : You may be eligible to participate in the class action against The Toronto-Dominion Bank. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by December 23, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP : Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders. To be notified if a class action against The Toronto-Dominion Bank settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.

SAN ANTONIO — Colorado secured what it said was record insurance coverage for quarterback Shedeur Sanders and Heisman Trophy winner Travis Hunter as the star duo opted to complete their college careers in the Alamo Bowl rather than sit out and prepare for the NFL draft. Colorado would not disclose the amount of insurance coverage each received, citing privacy laws. Coach Deion Sanders and athletic director Rick George both said it was the largest in college football history. "We happen to have two players that are probably going to be the first two picks of the NFL draft," Sanders said Monday. "We all know who those two are and they have received, I think, the highest number of coverage that has ever been covered in college football. It far exceeds anyone that has ever played this game of college football." While college programs maintain insurance policies for their athletes in case of injury, Colorado increased disability coverage for its entire roster in the Alamo Bowl. Sanders, the coach of the No. 20 Buffaloes, ensured his QB son and two-way star Hunter received larger policies since both are expected to be among the top 10 selections in the upcoming NFL draft. "It was his idea we should get disability insurance for our athletes for this game to ensure that they played and if there was some kind of injury that they would be well taken care of," George said. "So, we worked together on that. We're excited about it. We think it's great that all our players are playing in the game. That's what all bowl games should be like." Colorado (9-3, No. 23 CFP) will face the 17th-ranked BYU Cougars (10-2, No. 17 CFP) in the Alamo Bowl on Saturday. While most teams are scrambling with starters opting out of bowl games this year to enter the transfer portal or NFL draft, the Buffaloes did not lose any player on their two-deep roster. "It's more than what I got (when he played at Kansas State)," Colorado linebackers coach Andre' Hart said. "They gave us a helmet and said pop this on your leg and get out there and play. For them to get that (increased insurance coverage), I just think it's beneficial. To talk about where the game is, where it's going and how leadership is taking care of the players, I thought that's excellent." Shedeur Sanders completed 337 of 454 passes for 3,926 yards and 35 touchdowns this season. Many scouting services have Sanders rated as the top quarterback in this year's draft. Hunter received the Heisman Trophy as a two-way standout at cornerback and wide receiver. He had 92 receptions for 1,152 yards and 14 touchdowns and as a cornerback had four interceptions, broke up 11 passes and limited the opposition to 22 receptions on 688 defensive snaps. "They've taken care of us, everybody," Colorado running back Micah Welch said. "It really means a lot to have every teammate up here. That's a big thing. What I like about Coach Prime, they're taking care of us." Get local news delivered to your inbox!CENTURION (AFP): An emotional Temba Bavuma hailed the character of his team after South Africa qualified for the World Test championship final with a dramatic two-wicket win over Pakistan on the fourth day of the first Test at SuperSport Park on Sunday. Needing 148 to win, South Africa crashed to 99 for eight owing to superb bowling by Mohammad Abbas. But Kagiso Rabada turned batting hero as he and Marco Jansen took South Africa to victory with an unbeaten ninth wicket partnership of 51. Rabada, so often a match-winner as a bowler, went on the attack as a batsman, hitting an unbeaten 31 off 26 balls, while Jansen provided solid support in making 16 not out. “It is an emotional moment for me,” South African captain Bavuma said at the post-match presentation. “As a team, we have overcome a lot. We haven’t been super-dominant with our performances, we haven’t been ruthless but we have always found a way to ensure the result was on our side. “Today was testament to that. It speaks a lot to the talent and character of the group.” South Africa’s win meant that only one of Australia and India can qualify for the final at Lord’s in June. Pakistan captain Shan Masood said he was proud of the effort of his players but lamented the failure to take ruthless advantage of their opportunities. “Twice we had them eight down and with the bat we could have extended our first innings and could have extended our lead (in the second innings). We have to learn to seize the moments.” ‘The only spike’ Masood said Abbas, playing in his first Test in more than three years, had been “sensational”. The 34-year-old Abbas took a career-best six for 54. He bowled unchanged for 19.3 overs –- four of them on Saturday when he took his first two wickets -– in a spell of unremitting accuracy on a pitch which gave seam bowlers help throughout the match. Man of the match Aiden Markram and Bavuma batted solidly at the start of the day after resuming on 27 for three. However, Markram was bowled by Abbas for 37 by a virtually unplayable ball which kept low and seamed back off the pitch. Bavuma and David Bedingham added another 34 runs until Bavuma uncharacteristically charged down the pitch at Abbas and was given out caught behind for 40. He walked off immediately but Ultra Edge technology showed the only ‘spike’ was when the ball brushed his trouser pocket. It was the first of four wickets which fell for three runs in 12 balls. Naseem Shah bowled Kyle Verreynne and Abbas had Bedingham and Corbin Bosch caught behind off successive deliveries. Rabada and Jansen saw South Africa through to lunch at 116 for eight -– then polished off the match in just 5.3 overs after the interval, with each stroke cheered by the home spectators. Both sides have a short break before they meet for the second and final Test in Cape Town on January 3.

Jailed PKK leader says ‘ready’ to support Turkiye peace driveLOS ANGELES , Dec. 24, 2024 /PRNewswire/ -- Cadiz, Inc. (NASDAQ: CDZI / CDZIP) ("Cadiz," the "Company"), a California water solutions company, today announced that its Board of Directors has declared the following cash dividend on the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (the "Series A Preferred Stock"). Holders of Series A Preferred Stock will receive a cash dividend equal to $560.00 per whole share. Holders of depositary shares, each representing a 1/1000 fractional interest in a share of Series A Preferred Stock (Nasdaq: CDZIP), will receive a cash dividend equal to $0.56 per depositary share. The dividend will be paid on January 15, 2025 , to applicable holders of record as of the close of business on January 3, 2025 . About Cadiz, Inc. Founded in 1983, Cadiz, Inc. (NASDAQ: CDZI) is a California water solutions company dedicated to providing access to clean, reliable and affordable water for people through a unique combination of water supply, storage, pipeline and treatment solutions. With 45,000 acres of land in California , 2.5 million acre-feet of water supply, 220 miles of pipeline assets and the most cost-effective water treatment filtration technology in the industry, Cadiz offers a full suite of solutions to address the impacts of climate change on clean water access. For more information, please visit https://www.cadizinc.com . Safe Harbor Statement This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "anticipates", "expect", "may", "plan", or "will". Forward-looking statements include, without limitation, projections, predictions, expectations, or beliefs about future events or results and are not statements of historical fact, including statements regarding the Company's expectations regarding payments of dividends in the future. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified in our filings with the Securities and Exchange Commission (the "Commission"), including without limitation our Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Reports on Form 10-Q and other filings subsequently made by the Company with the Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. View original content to download multimedia: https://www.prnewswire.com/news-releases/cadiz-inc-declares-quarterly-dividend-for-q4-2024-on-series-a-cumulative-perpetual-preferred-stock-302339009.html SOURCE Cadiz, Inc.

Elon Musk's efforts to get his massive $56 billion 2018 Tesla pay package reinstated was rejected by a Delaware judge on Monday. The decision, issued by Delaware Chancery Court Judge Kathaleen St. J. McCormick, comes after a majority of Tesla shareholders in August reauthorized the compensation package during the electric vehicle maker's annual meeting. After it was initially approved in 2018, the pay package sparked a lawsuit from some Tesla shareholders who accused Musk and Tesla's board of directors of breaching their duties and unjustly enriching the billionaire. In January 2024, McCormick had ruled that Musk and his company failed to prove that the huge payout was legally warranted, prompting Musk to take the issue back to his shareholders in August. In her Dec. 2 decision, McCormick said that Musk had asked the court "to flip its decision and enter judgment in their favor." She added, "The motion to revise is denied," citing what the judge described as "at least four fatal flaws" in arguments from Musk's attorneys. "The large and talented group of defense firms got creative with the ratification argument, but their unprecedented theories go against multiple strains of settled law," McCormick noted. Tesla did not immediately respond to a request for comment. Shares of Tesla fell slightly in after-hours trading, dipping $4.74, or 1.3%, to $352.35. The stock has gained 47% in the last month, buoyed by investor optimism that President-elect Donald Trump's victory at the polls will help boost Tesla's prospects, given Musk's support for his campaign . The stock options Tesla granted to Musk were initially worth $2.6 billion but had soared to $56 billion when McCormick blocked the package in January, according to Bloomberg News . "No basis in the common law" Musk's attorneys had argued that the second vote made clear that Tesla shareholders, with full knowledge of the flaws in the 2018 process that McCormick had earlier pointed out, were adamant that Musk is entitled to the pay package. They asked the judge to vacate her order directing Tesla to rescind the pay package. Among the issues in their latest arguments, McCormick wrote, was a lack of procedural grounds for "flipping the outcome of an adverse post-trial decision based on evidence they created after trial." She also objected to Musk's attempt to recertify the pay package through another shareholder vote, which she wrote his attorneys had argued served as "common law ratification." "What the defendants call 'common law ratification' has no basis in the common law — a stockholder vote standing alone cannot ratify a conflicted-controller transaction," she noted. "[E]ven if a stockholder vote could have a ratifying effect, it could not do so here due to multiple, material misstatements in the proxy statement." McCormick also rejected an equally unprecedented and massive fee request by plaintiff attorneys, who argue they were entitled to legal fees in the form of Tesla stock valued at more than $5 billion. The judge said the attorneys were entitled to a fee award of $345 million. Despite the setback, Musk remains the world's wealthiest person, with a net worth of $343 billion, according to the Bloomberg Billionaires Index. The Associated Press contributed to this report. Tesla Elon Musk Aimee Picchi is the associate managing editor for CBS MoneyWatch, where she covers business and personal finance. She previously worked at Bloomberg News and has written for national news outlets including USA Today and Consumer Reports.

NBA Christmas Day Games on ESPN to Bring Animated Disney Characters in Real-Time BroadcastSaudi Arabia: One dead, 10 injured in 20-vehicle collisionRNA Therapeutics Market Future Trends, New Opportunities, Business Growth, Share, Global Size, Demand, Key Segments And Forecast 12-13-2024 08:42 PM CET | Health & Medicine Press release from: ABNewswire The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US) Browse 135 market data Tables and 36 Figures spread through 171 Pages and in-depth TOC on "RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028 RNA Therapeutics Market [ https://www.marketsandmarkets.com/Market-Reports/rna-therapeutics-market-235963408.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] in terms of revenue was estimated to be worth $13.7 billion in 2023 and is poised to reach $18.0 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028 according to a new report by MarketsandMarkets Trademark . Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (saRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics. saRNAs are 21-nucleotide long double-stranded RNAs (dsRNAs) complementary to the promoter region of a targeted gene. They can upregulate gene expression, potentially correcting deficiencies associated with genetic disorders and re-activating tumor suppressor genes in multiple types of cancers. On the other hand, the discontinuation/recalls of RNA therapeutic products is expected to hinder market growth. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235963408 [ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] The vaccines segment accounted for the largest share of the RNA therapeutics market in 2022. Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented majority of the market share and is anticipated to maintain this dominance throughout the forecast period. Two key vaccine products that have showcased majority revenue contribution in this segment, include Spikevax (Moderna, Inc.) and Comirnaty (Pfizer, Inc.) vaccines. Additionally, these COVID-19 vaccines showcased a considerable revenue growth between from 2021 and 2022. On the other hand, the recent recall/discontinuation of Spikevax (Moderna, Inc.) is anticipated to hinder the revenue growth post 2022. Increase in the development of innovative RNA medicine companies in the RNA therapeutics market has rendered it the fastest growing segment during the forecast period. The RNA interference (RNAi) therapeutics segment is expected to grow at the highest CAGR from 2023 to 2028. Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. Factors associated with RNA interference (RNAi) therapeutics such as precision and versatility have increased the potential of RNAi applications in personalized medicine and other clinical applications. On the other hand, the mRNA therapeutics segment accounted for the highest share in the global market in 2022 and is expected to maintain this trend through 2021-2028. The advantages of mRNA over DNA or proteins/peptides coupled with advent of novel vaccine and molecular entities are the key attributive reason to this dominance. The infectious diseases segment accounted for the largest share in the RNA therapeutics market in 2022. Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. The large share of the infectious diseases segment is a result of the rapid developments in RNA vaccine manufacturing capabilities for the treatment of infectious diseases along with the outbreak of COVID-19. Demand for mRNA vaccines grew significantly through 2021-2022, for immunization against SARS-COV-2 infection. Increase in the use of RNA-based therapeutics for the treatment of rare/genetic disorders contributes to the high share of hospitals & clinics. The RNA therapeutics market is segmented into hospitals and clinics and research settings. The growing use of RNA therapeutics across hospitals and clinics is driven by factors such as the increasing understanding and advancements of RNA-based therapeutics, the growing number of trends in personalized medicine, the increasing prevalence of chronic diseases, and the rising research investments by governments, private foundations, and industry stakeholders. Europe dominates the global RNA therapeutics market throughout the forecast period. The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with highest share of revenue in this segment in 2022. North America has emerged as the fastest growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs is highest in 2022, and this is set to continue through the forecast period. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=235963408 [ https://www.marketsandmarkets.com/requestsampleNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] RNA Therapeutics Market Dynamics: Drivers: 1. Increasing partnerships and collaborations among market players and RNA technology manufacturers Restraints: 1. Discontinuation or recalls of RNA therapeutic products Opportunities: 1. Higher progress in the development of RNA aptamer-based therapeutics Challenge: 1. Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA Key Market Players: The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Sanofi (France), Arrowhead Pharmaceuticals, Inc. (US), BioNtech SE (Germany), Orna Therapeutics (US), CRISPR Therapeutics (Switzerland), Silence Therapeutics (UK), Astellas Pharma Inc. (Japan), CureVac SE (Germany), Sirnaomics (US), Arcturus Therapeutics Inc. (US) and Arbutus Biopharma (US). Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=235963408 [ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=235963408&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] RNA Therapeutics Market Advantages: * Precision Medicine: RNA-based therapies can be tailored to target specific genetic mutations or disease pathways, allowing for personalized treatments that are more effective and have fewer side effects. * Speed of Development: The rapid development of RNA-based vaccines during the COVID-19 pandemic demonstrated the agility of this technology, which can potentially accelerate the response to emerging diseases and medical challenges. * Versatility: RNA can be engineered to address a wide range of diseases, including genetic disorders, cancer, infectious diseases, and rare diseases, making it a versatile platform for therapeutic development. * Reduced Off-Target Effects: Compared to traditional small molecule drugs, RNA therapies can have a higher degree of specificity, minimizing off-target effects on healthy cells and tissues. * Lower Manufacturing Costs: Advances in RNA synthesis and production techniques are driving down manufacturing costs, potentially making RNA therapies more accessible and affordable. * Targeting Undruggable Proteins: RNA therapeutics can target proteins that were previously considered "undruggable" with small molecules, expanding the range of potential drug targets. * Potential for Gene Editing: RNA-based therapies, such as CRISPR-Cas9, hold promise for precise gene editing and the treatment of genetic diseases at their root cause. * Immunomodulation: RNA molecules can be designed to stimulate or inhibit immune responses, making them valuable tools in the treatment of autoimmune diseases and for enhancing cancer immunotherapies. * Reduced Development Risk: The ability to rapidly iterate and optimize RNA therapies in preclinical and clinical stages can reduce the risks associated with drug development. * Therapeutic Innovation: RNA therapeutics represent a novel class of drugs that can complement existing treatment modalities, offering innovative solutions to unmet medical needs. Media Contact Company Name: MarketsandMarkets Trademark Research Private Ltd. Contact Person: Mr. Rohan Salgarkar Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=rna-therapeutics-market-future-trends-new-opportunities-business-growth-share-global-size-demand-key-segments-and-forecast ] Phone: 18886006441 Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 City: Florida State: Florida Country: United States Website: https://www.marketsandmarkets.com/Market-Reports/rna-therapeutics-market-235963408.html This release was published on openPR.

Last Chance For The Sdgs?

Analysis: Protecting QBs from violent late hits like the one that leveled Trevor Lawrence isn't easy

By MICHAEL R. SISAK and JENNIFER PELTZ NEW YORK (AP) — President-elect Donald Trump’s lawyers urged a judge again Friday to throw out his hush money conviction, balking at the prosecution’s suggestion of preserving the verdict by treating the case the way some courts do when a defendant dies. They called the idea “absurd.” Related Articles National Politics | Trump wants to turn the clock on daylight saving time National Politics | Ruling by a conservative Supreme Court could help blue states resist Trump policies National Politics | A nonprofit leader, a social worker: Here are the stories of the people on Biden’s clemency list National Politics | Nancy Pelosi hospitalized after she ‘sustained an injury’ on official trip to Luxembourg National Politics | Veteran Daniel Penny, acquitted in NYC subway chokehold, will join Trump’s suite at football game The Manhattan district attorney’s office is asking Judge Juan M. Merchan to “pretend as if one of the assassination attempts against President Trump had been successful,” Trump’s lawyers wrote in a blistering 23-page response. In court papers made public Tuesday, District Attorney Alvin Bragg’s office proposed an array of options for keeping the historic conviction on the books after Trump’s lawyers filed paperwork earlier this month asking for the case to be dismissed. They include freezing the case until Trump leaves office in 2029, agreeing that any future sentence won’t include jail time, or closing the case by noting he was convicted but that he wasn’t sentenced and his appeal wasn’t resolved because of presidential immunity. Trump lawyers Todd Blanche and Emil Bove reiterated Friday their position that the only acceptable option is overturning his conviction and dismissing his indictment, writing that anything less will interfere with the transition process and his ability to lead the country. The Manhattan district attorney’s office declined comment. It’s unclear how soon Merchan will decide. He could grant Trump’s request for dismissal, go with one of the prosecution’s suggestions, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court, or choose some other option. In their response Friday, Blanche and Bove ripped each of the prosecution’s suggestions. Halting the case until Trump leaves office would force the incoming president to govern while facing the “ongoing threat” that he’ll be sentenced to imprisonment, fines or other punishment as soon as his term ends, Blanche and Bove wrote. Trump, a Republican, takes office Jan. 20. “To be clear, President Trump will never deviate from the public interest in response to these thuggish tactics,” the defense lawyers wrote. “However, the threat itself is unconstitutional.” The prosecution’s suggestion that Merchan could mitigate those concerns by promising not to sentence Trump to jail time on presidential immunity grounds is also a non-starter, Blanche and Bove wrote. The immunity statute requires dropping the case, not merely limiting sentencing options, they argued. Blanche and Bove, both of whom Trump has tabbed for high-ranking Justice Department positions, expressed outrage at the prosecution’s novel suggestion that Merchan borrow from Alabama and other states and treat the case as if Trump had died. Blanche and Bove accused prosecutors of ignoring New York precedent and attempting to “fabricate” a solution “based on an extremely troubling and irresponsible analogy between President Trump” who survived assassination attempts in Pennsylvania in July and Florida in September “and a hypothetical dead defendant.” Such an option normally comes into play when a defendant dies after being convicted but before appeals are exhausted. It is unclear whether it is viable under New York law, but prosecutors suggested that Merchan could innovate in what’s already a unique case. “This remedy would prevent defendant from being burdened during his presidency by an ongoing criminal proceeding,” prosecutors wrote in their filing this week. But at the same time, it wouldn’t “precipitously discard” the “meaningful fact that defendant was indicted and found guilty by a jury of his peers.” Prosecutors acknowledged that “presidential immunity requires accommodation” during Trump’s impending return to the White House but argued that his election to a second term should not upend the jury’s verdict, which came when he was out of office. Longstanding Justice Department policy says sitting presidents cannot face criminal prosecution . Other world leaders don’t enjoy the same protection. For example, Israeli Prime Minister Benjamin Netanyahu is on trial on corruption charges even as he leads that nation’s wars in Lebanon and Gaza . Trump has been fighting for months to reverse his May 30 conviction on 34 counts of falsifying business records . Prosecutors said he fudged the documents to conceal a $130,000 payment to porn actor Stormy Daniels to suppress her claim that they had sex a decade earlier, which Trump denies. In their filing Friday, Trump’s lawyers citing a social media post in which Sen. John Fetterman used profane language to criticize Trump’s hush money prosecution. The Pennsylvania Democrat suggested that Trump deserved a pardon, comparing his case to that of President Joe Biden’s pardoned son Hunter Biden, who had been convicted of tax and gun charges . “Weaponizing the judiciary for blatant, partisan gain diminishes the collective faith in our institutions and sows further division,” Fetterman wrote Wednesday on Truth Social. Trump’s hush money conviction was in state court, meaning a presidential pardon — issued by Biden or himself when he takes office — would not apply to the case. Presidential pardons only apply to federal crimes. Since the election, special counsel Jack Smith has ended his two federal cases , which pertained to Trump’s efforts to overturn his 2020 election loss and allegations that he hoarded classified documents at his Mar-a-Lago estate. A separate state election interference case in Fulton County, Georgia, is largely on hold. Trump denies wrongdoing in all. Trump had been scheduled for sentencing in the hush money case in late November. But following Trump’s Nov. 5 election victory, Merchan halted proceedings and indefinitely postponed the former and future president’s sentencing so the defense and prosecution could weigh in on the future of the case. Merchan also delayed a decision on Trump’s prior bid to dismiss the case on immunity grounds. A dismissal would erase Trump’s conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office.Loo-less town's battle illustrates national problem